# The Thing That Makes Regain Inevitable

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-20 | Updated: 2026-10-27

Canonical page: https://glpwatchdog.org/research/the-thing-that-makes-regain-inevitable

> Metabolic adaptation is the leading explanation for why weight loss plateaus and returns. A study asked whether tirzepatide interrupts it. In mice it did; in people it did not.

## Key points

- Tirzepatide blunted metabolic adaptation in MICE and appeared to do nothing in PEOPLE.
- The paper's title reports the human result, which is to the authors' credit.
- The second rodent plateau mechanism this corpus has covered that did not carry over.
- What did carry over: increased fat oxidation. People also ate less at a weighed meal.
- So the drug changes what you eat and what you burn it as, not how much energy you spend.
- 'No impact' in a phase 1 study is an underpowered null, not proof of absence.

When you lose weight, your body burns less energy than its new size predicts, and it keeps doing so. That gap, called metabolic adaptation, is the leading explanation for why weight loss plateaus and why it comes back. A study asked whether tirzepatide interrupts it. In mice it did. **In people it did not.**[1]

## What metabolic adaptation is

A smaller body needs less fuel, and everyone expects energy expenditure to fall as weight comes off. Metabolic adaptation is the part that falls *further than that*: a reduction beyond what the change in body size accounts for, and one that persists rather than resolving.

It is why maintaining a reduced weight is harder than reaching it, and it is a large part of why the same eating that produced weight loss stops producing it. Any drug that switched it off would be doing something new.

## The mouse result and the human result

*The same investigation, in two species.[1]*

|   | Calorie-restricted obese mice | People with obesity (phase 1) |
| --- | --- | --- |
| **Metabolic adaptation** | **Attenuated** — less of the drop in energy expenditure seen in vehicle-treated and pair-fed animals | **No apparent impact** |
| Fat oxidation | Increased | **Increased** |
| Appetite and calorie intake | — | Reduced at an ad libitum test meal |

The mouse arm is a careful design. Comparing against *pair-fed* animals (ones fed the same reduced amount without the drug) separates the effect of eating less from the effect of the drug. On that comparison, tirzepatide blunted the fall in energy expenditure.

> The mechanism worked in mice and did not appear in people. The paper's title reports the human result.

The authors deserve credit for that title. A study with a positive animal finding and a null human one could easily have led with the mouse. This one did not.

## This is the second time

> **We have now covered two rodent mechanisms for the weight-loss plateau, and neither has been confirmed in people.** The other is a dopamine circuit that recovers its activity during continued treatment, restoring appetite for palatable food. That work, covered in [why the appetite comes back](https://glpwatchdog.org/research/why-the-appetite-comes-back), was also entirely in mice.

Keep that pattern in mind whenever a mechanism story appears. Mice are where mechanisms get established, because you can do things to a mouse you cannot do to a person. They are also where mechanisms most often stop.

## What did carry over

One effect appeared in both species. **Fat oxidation increased**: the body shifted toward burning fat rather than carbohydrate, without total expenditure changing. In people, appetite and calorie intake also fell at a laboratory meal with unlimited access.

That second measurement is the one we covered separately from the same research program, where participants ate 524.6 fewer calories at a single weighed lunch without any increase in deliberate restraint (see [five hundred calories at one lunch](https://glpwatchdog.org/research/five-hundred-calories-at-one-lunch)).

Together those give a coherent account of how the drug works, and it is a narrower one than people assume: **it changes what you eat and what you burn it as, not how much energy you spend.** The semaglutide measurements point the same way; see [does Ozempic slow your metabolism](https://glpwatchdog.org/research/does-ozempic-slow-your-metabolism).

## What follows, and what does not

> **“No impact” in a phase 1 study is an underpowered null, not a demonstration of absence.** This was a small, short mechanistic trial. It is entirely possible that tirzepatide has a real effect on metabolic adaptation that a study this size could not see, and the authors describe it as tirzepatide *appearing* to have no impact rather than as having none.

Within that limit, the practical implication is unwelcome. If metabolic adaptation is untouched, then the physiological pressure that makes maintenance hard is still there while someone is on the drug, and it is waiting when they come off. That is consistent with what the withdrawal trials show (see [what happens when you stop](https://glpwatchdog.org/research/what-happens-when-you-stop-a-glp1)) and with regain being biology rather than a failure of resolve.

It also fits the shape of the plateau. Weight loss slowing after six to eight months is what a curve does when the drug reduces intake while the body’s defense of its weight continues uninterrupted. The timings are in [what a plateau actually means](https://glpwatchdog.org/research/what-a-plateau-actually-means).

The authors are employees of the company that makes tirzepatide, which is ordinary for a mechanistic phase 1 program. It also means they are reporting a null result about their own drug.

## Frequently asked questions

### What is metabolic adaptation?

The drop in energy expenditure during weight loss that goes beyond what the smaller body size accounts for, and persists. It is the leading explanation for why weight loss plateaus and why weight returns.

### Does tirzepatide prevent it?

Not in people, on this evidence. In calorie-restricted obese mice the drug blunted the fall in energy expenditure, but in a phase 1 clinical trial it appeared to have no impact on metabolic adaptation.

### Does that mean the drug does not work on metabolism?

It works on fuel use rather than on total expenditure. Fat oxidation increased in both mice and people, and appetite and calorie intake fell. The drug changes what you eat and what you burn it as, not how much energy you spend.

### Why does this matter for regain?

If the adaptation is untouched, the physiological pressure that defends a higher weight is still operating during treatment and still waiting afterward. That is consistent with what withdrawal trials show and supports regain being biology rather than a failure of effort.

### How certain is the human result?

Not very. A phase 1 study is small and short, so a null finding is an underpowered one. The authors describe the drug as appearing to have no impact rather than as having none.

## References

1. Ravussin E, Sanchez-Delgado G, Martin CK, et al. Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation. Cell Metabolism. 2025. PMID: 40203836. https://pubmed.ncbi.nlm.nih.gov/40203836/

---

Cite as: GLP Watchdog, Nora Bissett, "The Thing That Makes Regain Inevitable", published 2026-08-20, updated 2026-10-27. https://glpwatchdog.org/research/the-thing-that-makes-regain-inevitable

Canonical HTML page: https://glpwatchdog.org/research/the-thing-that-makes-regain-inevitable

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
